標(biāo)題: Titlebook: Current Understanding and Treatment of Gliomas; Jeffrey Raizer,Andrew Parsa Book 2015 Springer International Publishing Switzerland 2015 C [打印本頁(yè)] 作者: Covenant 時(shí)間: 2025-3-21 20:00
書目名稱Current Understanding and Treatment of Gliomas影響因子(影響力)
書目名稱Current Understanding and Treatment of Gliomas影響因子(影響力)學(xué)科排名
書目名稱Current Understanding and Treatment of Gliomas網(wǎng)絡(luò)公開度
書目名稱Current Understanding and Treatment of Gliomas網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Current Understanding and Treatment of Gliomas被引頻次
書目名稱Current Understanding and Treatment of Gliomas被引頻次學(xué)科排名
書目名稱Current Understanding and Treatment of Gliomas年度引用
書目名稱Current Understanding and Treatment of Gliomas年度引用學(xué)科排名
書目名稱Current Understanding and Treatment of Gliomas讀者反饋
書目名稱Current Understanding and Treatment of Gliomas讀者反饋學(xué)科排名
作者: 供過(guò)于求 時(shí)間: 2025-3-21 23:53
Glioma Biology and Molecular Markers,on histologies (oligodendroglioma, mixed oligoastrocytoma, pilocytic astrocytoma). Recent efforts at comprehensive genetic characterization of various primary brain tumor types have identified a number of common alterations and pathways common to multiple tumor types. Common pathways in glioma biolo作者: Dri727 時(shí)間: 2025-3-22 04:26
Surgery for Gliomas, to achieve this goal while minimizing the risk of postoperative neurologic deficits, intraoperative brain mapping remains the gold standard. Recent advances in technical aspects of preoperative and intraoperative brain mapping, as well as our understanding of the functional anatomy of the human bra作者: Rodent 時(shí)間: 2025-3-22 08:20
Radiation Therapy of Glioblastoma,have been demonstrated with postoperative radiation therapy (RT) to doses of 5,000–6,000?cGy but dose-escalation attempts beyond 6,000?cGy have resulted in increased toxicity but no additional survival benefit. To improve local control and limit toxicity to normal brain tissue with these infiltratin作者: CRAFT 時(shí)間: 2025-3-22 11:37
Low-Grade Glioma,een 4.7 and 9.8?years. The goal of treatment is to prolong overall survival while maintaining good quality of life (QOL). Recent data favors early surgical resection. EOR is associated with delayed tumor recurrence and improved survival. Additional therapy with chemotherapy or radiation is indicated作者: IVORY 時(shí)間: 2025-3-22 14:49 作者: IVORY 時(shí)間: 2025-3-22 20:14 作者: 胖人手藝好 時(shí)間: 2025-3-22 23:42
Novel Chemotherapeutic Approaches in Adult High-Grade Gliomas,f the genetic and molecular aberrations that contribute to the aggressive nature of these tumors is continually growing, as is our ability to target such specific traits. Herein, we review the major classes of such targeted therapies, as well as the relevant clinical trial outcomes regarding their e作者: 過(guò)濾 時(shí)間: 2025-3-23 02:30
Immunotherapy for Malignant Gliomas,omas is an emerging field that promises the possibility of highly specific and less toxic treatment compared to conventional chemotherapy. In addition, immunotherapy has the added benefit of sustained efficacy once immunologic memory is induced. Although there are numerous therapeutic agents that bo作者: confide 時(shí)間: 2025-3-23 05:39 作者: 分貝 時(shí)間: 2025-3-23 13:45
Palliative and Supportive Care for Glioma Patients,ited. While low-grade glioma patients have better outcomes, their quality of life is often affected by a variety of symptoms as well. Helping glioma patients improve quality of life at all stages of illness is an important goal for the interdisciplinary care team. There is evidence from advanced lun作者: Maximize 時(shí)間: 2025-3-23 15:35
Jeffrey Raizer,Andrew ParsaDescribes current treatment approaches and novel therapies.Explains the importance of advances in understanding of glioma biology.Discusses new clinical trial designs.Includes supplementary material: 作者: 新手 時(shí)間: 2025-3-23 21:39
Cancer Treatment and Researchhttp://image.papertrans.cn/d/image/241492.jpg作者: 震驚 時(shí)間: 2025-3-24 01:08 作者: crucial 時(shí)間: 2025-3-24 05:07
Von Nannas Herden zu Helios’ Rindernon histologies (oligodendroglioma, mixed oligoastrocytoma, pilocytic astrocytoma). Recent efforts at comprehensive genetic characterization of various primary brain tumor types have identified a number of common alterations and pathways common to multiple tumor types. Common pathways in glioma biolo作者: 主動(dòng)脈 時(shí)間: 2025-3-24 10:20 作者: 叫喊 時(shí)間: 2025-3-24 13:10 作者: Panacea 時(shí)間: 2025-3-24 14:57
https://doi.org/10.1007/978-3-662-68110-7een 4.7 and 9.8?years. The goal of treatment is to prolong overall survival while maintaining good quality of life (QOL). Recent data favors early surgical resection. EOR is associated with delayed tumor recurrence and improved survival. Additional therapy with chemotherapy or radiation is indicated作者: 大門在匯總 時(shí)間: 2025-3-24 21:10 作者: seruting 時(shí)間: 2025-3-25 02:48 作者: 詩(shī)集 時(shí)間: 2025-3-25 04:54
,1924, Einführung: Vorarbeiten,f the genetic and molecular aberrations that contribute to the aggressive nature of these tumors is continually growing, as is our ability to target such specific traits. Herein, we review the major classes of such targeted therapies, as well as the relevant clinical trial outcomes regarding their e作者: 功多汁水 時(shí)間: 2025-3-25 07:52 作者: irradicable 時(shí)間: 2025-3-25 13:37 作者: 散開 時(shí)間: 2025-3-25 16:39
https://doi.org/10.1007/978-3-662-68752-9ited. While low-grade glioma patients have better outcomes, their quality of life is often affected by a variety of symptoms as well. Helping glioma patients improve quality of life at all stages of illness is an important goal for the interdisciplinary care team. There is evidence from advanced lun作者: disrupt 時(shí)間: 2025-3-25 22:42
Novel Chemotherapeutic Approaches in Adult High-Grade Gliomas,f the genetic and molecular aberrations that contribute to the aggressive nature of these tumors is continually growing, as is our ability to target such specific traits. Herein, we review the major classes of such targeted therapies, as well as the relevant clinical trial outcomes regarding their efficacy.作者: Hyperalgesia 時(shí)間: 2025-3-26 00:09 作者: 使習(xí)慣于 時(shí)間: 2025-3-26 04:59 作者: 和平 時(shí)間: 2025-3-26 08:47 作者: Ostrich 時(shí)間: 2025-3-26 15:57 作者: 范例 時(shí)間: 2025-3-26 18:39 作者: chapel 時(shí)間: 2025-3-26 22:56
?rztliche Begutachtung von A - Zm supportive care only, radiation therapy (RT) only (most often given in a shortened hypofractionated schedule), temozolomide (TMZ) chemotherapy only, and the combination RT?+?TMZ, followed by post-RT TMZ as is the current standard of care for younger good performance patients with newly diagnosed GBM.作者: Phenothiazines 時(shí)間: 2025-3-27 03:35 作者: indifferent 時(shí)間: 2025-3-27 05:29 作者: 過(guò)濾 時(shí)間: 2025-3-27 09:42
Radiation Therapy of Glioblastoma,t tend to be associated with notable toxicity. More recently, re-irradiation strategies employ concurrent use of bevacizumab to limit treatment-related injury while still permitting delivery of meaningful doses. These clinical trials are ongoing and merits of these strategies are not yet clear but a作者: 啞劇 時(shí)間: 2025-3-27 14:24 作者: Alveoli 時(shí)間: 2025-3-27 20:50
Immunotherapy for Malignant Gliomas,osuppression. The mechanisms of immunosuppression are only now being elucidated, but clearly involve a combination of factors including regulatory T cells, tumor-associated PD-L1 expression, and CTLA-4 signaling. Immunomodulatory agents have been developed to combat these immunosuppressive factors a作者: Wernickes-area 時(shí)間: 2025-3-28 00:34 作者: Pathogen 時(shí)間: 2025-3-28 06:07
Von Nannas Herden zu Helios’ Rindernmutations or fusions in the BRAF gene seen in pilocytic astrocytomas (and gangliogliomas). In oligodendrogliomas, mutations in IDH1 and codeletion of chromosomes 1p and 19q are associated with improved survival with upfront use of combined chemotherapy and radiation, and these tumors also have uniqu作者: Dna262 時(shí)間: 2025-3-28 08:47
Von Nannas Herden zu Helios’ Rindernt tend to be associated with notable toxicity. More recently, re-irradiation strategies employ concurrent use of bevacizumab to limit treatment-related injury while still permitting delivery of meaningful doses. These clinical trials are ongoing and merits of these strategies are not yet clear but a作者: 大量殺死 時(shí)間: 2025-3-28 12:52
https://doi.org/10.1007/978-3-662-68110-7s. In the CIMP-negative, mainly . wild-type group, MGMT promoter methylation may be used to identify patients who benefit from alkylating chemotherapy. The mutually exclusive ATRX losses and 1p/19q codeletions are used to subcategorize anaplastic tumors with a mixed histology according to microscopi作者: 許可 時(shí)間: 2025-3-28 17:09
https://doi.org/10.1007/978-3-662-68575-4osuppression. The mechanisms of immunosuppression are only now being elucidated, but clearly involve a combination of factors including regulatory T cells, tumor-associated PD-L1 expression, and CTLA-4 signaling. Immunomodulatory agents have been developed to combat these immunosuppressive factors a作者: BRACE 時(shí)間: 2025-3-28 20:18
https://doi.org/10.1007/978-3-662-68752-9on, and anxiety are some of the more common symptoms throughout the disease course and should be managed actively. Patients with glioma also have high symptom burden at the end of life and the majority lose decision-making capacity. Advance care planning conversations early in the disease course are作者: 使饑餓 時(shí)間: 2025-3-29 00:26
Book 2015nt, ?investigating emerging therapies from small molecules to immunotherapy and palliative care. This timely book will be a valuable source of up-to-date information for practitioners and will also be of interest to researchers..作者: Feigned 時(shí)間: 2025-3-29 04:01
Die Zahlentheorie im antiken Orientciation study (GWAS) design, have identified several inherited risk variants that are associated with increased glioma risk. The following chapter provides an overview of the current state of research in the epidemiology of intracranial glioma.作者: thalamus 時(shí)間: 2025-3-29 07:46 作者: insomnia 時(shí)間: 2025-3-29 12:24
Epidemiology of Gliomas,ciation study (GWAS) design, have identified several inherited risk variants that are associated with increased glioma risk. The following chapter provides an overview of the current state of research in the epidemiology of intracranial glioma.作者: octogenarian 時(shí)間: 2025-3-29 18:33 作者: Asparagus 時(shí)間: 2025-3-29 19:43 作者: 新鮮 時(shí)間: 2025-3-30 00:21
Current Medical Treatment of Glioblastoma,section with or without the placement of carmustine wafers, re-irradiation and chemotherapeutics such as nitrosoureas (lomustine, carmustine) or bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF).作者: 思想 時(shí)間: 2025-3-30 05:53 作者: 來(lái)就得意 時(shí)間: 2025-3-30 08:58
